Related Experiment Video
Updated: May 12, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Botulinum toxin A and headache treatment
1University of Connecticut, CT 06708, USA.
Botulinum toxin type A (BOTOX) shows a modest effect for preventing chronic migraine and tension-type headaches. Further research is needed to confirm its effectiveness in headache treatment.
Area of Science:
- Neurology
- Pharmacology
Background:
- Headaches, including chronic migraine and tension-type headaches, significantly impact quality of life.
- Prophylactic treatments aim to reduce headache frequency and intensity.
Purpose of the Study:
- To evaluate the efficacy of botulinum toxin type A (BOTOX) as a prophylactic treatment for headaches in adults.
- To review existing literature on BOTOX for chronic migraine and tension-type headaches.
Main Methods:
- A retrospective literature review was conducted.
- Analysis of outcomes from various studies investigating BOTOX for headache treatment.
Main Results:
- The PREEMPT trial demonstrated a statistically significant decrease in headache days and hours for migraine treatment.
- Studies on chronic tension-type headaches show mixed results, with most indicating no significant difference in intensity.
- The effectiveness of BOTOX for chronic migraine and tension-type headaches remains debated.
Conclusions:
- Current literature suggests a modest prophylactic effect of botulinum toxin type A for chronic migraine and tension-type headaches.
- Further prospective, randomized, double-blinded studies are required to definitively establish efficacy.
- The role of BOTOX in headache prophylaxis warrants continued investigation.
More Related Videos
12:25Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
10:30A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...